-
ALSO READ
Sharon Bio-Medicine reports standalone net loss of Rs 21.83 crore in the September 2017 quarter Torrent Pharmaceuticals acquires US based Bio-Pharm Inc. Strides Shasun arm gets USFDA nod for HIV drug Lupin gets USFDA nod for generic psoriasis treatment solution Cipla gets USFDA approval for HIV drug -
Sales rise 19.37% to Rs 38.88 crore
Net profit of Sharon Bio-Medicine reported to Rs 0.69 crore in the quarter ended December 2017 as against net loss of Rs 1.91 crore during the previous quarter ended December 2016.Sales rose 19.37% to Rs 38.88 crore in the quarter ended December 2017 as against Rs 32.57 crore during the previous quarter ended December 2016. ParticularsQuarter EndedDec. 2017Dec. 2016% Var.Sales38.8832.57 19 OPM %9.770.92 -PBDT3.80-5.07 LP PBT0.75-9.89 LP NP0.69-1.91 LP
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU